- Home
- NAGE vs KOD Comparison
NAGE vs KOD Comparison
Compare NAGE & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAGE | KOD |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 766.4M | 795.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | NAGE | KOD |
|---|---|---|
| Price | $6.37 | $22.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $16.33 | ★ $22.67 |
| AVG Volume (30 Days) | ★ 748.2K | 720.6K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1093.81 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $124,709,000.00 | N/A |
| Revenue This Year | $30.37 | N/A |
| Revenue Next Year | $20.36 | N/A |
| P/E Ratio | $27.76 | ★ N/A |
| Revenue Growth | ★ 36.04 | N/A |
| 52 Week Low | $5.16 | $1.92 |
| 52 Week High | $14.69 | $26.21 |
Technical Indicators
Market Signals| Indicator | NAGE | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 37.92 | 54.93 |
| Support Level | $6.40 | $21.24 |
| Resistance Level | $6.77 | $26.21 |
| Average True Range (ATR) | 0.22 | 1.67 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 3.77 | 40.65 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.